LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

Alvotech and Dr Reddy's entered into a collaboration and license agreement to co-develop, manufacture and commercialize a ...

Dr. Reddy's Laboratories Ltd. closed 9.17% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Dr Reddy's shares soar 3.54% after Alvotech partnership for Keytruda biosimilar, enhancing global reach in cancer ...

Dr. Reddys shares rose over 4% after announcing a global biosimilar partnership with Alvotech for Keytruda. Q4FY25 profit ...

HSBC upgraded Dr Reddy’s Laboratories to Buy from Hold and raised its target price to INR 1445, citing expectations that sales of semaglutide, a generic version of Novo Nordisk’s blockbuster ...

Dr. Reddy's Laboratories and Alvotech have partnered to co-develop, manufacture, and commercialize a biosimilar of Keytruda ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...